synthetic lethal mutations


Summary: Mutations in genes which lead to cell or organism death when occurring in combination with mutations in one or more other genes.

Top Publications

  1. Downey M, Baetz K. Building a KATalogue of acetyllysine targeting and function. Brief Funct Genomics. 2016;15:109-18 pubmed publisher
    ..Here, we review these methods in the context of their contributions to acetylation research thus far and suggest strategies for addressing lingering questions in the field. ..
  2. Lord C, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355:1152-1158 pubmed publisher
    ..Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness. ..
  3. Nickoloff J, Jones D, Lee S, Williamson E, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst. 2017;109: pubmed publisher
    ..In addition, future therapies will exploit artificial synthetic lethality, where complementary DNA repair pathways are targeted simultaneously in cancers without DNA repair defects. ..
  4. Gómez Herreros F, Margaritis T, Rodríguez Galán O, Pelechano V, Begley V, Millán Zambrano G, et al. The ribosome assembly gene network is controlled by the feedback regulation of transcription elongation. Nucleic Acids Res. 2017;45:9302-9318 pubmed publisher
    ..On the whole, this work uncovers a feedback control of ribosome biogenesis by fine-tuning transcription elongation in ribosome assembly factor-coding genes. ..
  5. Dolly S, Gurden M, Drosopoulos K, Clarke P, de Bono J, Kaye S, et al. RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. Br J Cancer. 2017;117:954-964 pubmed publisher
    ..These data suggest a putative therapeutic strategy for a large number of different types of human cancers with FBXW7 loss, many of which have a paucity of molecular abnormalities and treatment options. ..
  6. Vyse S, Howitt A, Huang P. Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. J Mol Biol. 2017;429:1767-1786 pubmed publisher
    ..We conclude by presenting a number of tangible steps to bolster our understanding of fundamental synthetic lethality mechanisms and advance these findings beyond the confines of the laboratory. ..
  7. Pan R, Ruvolo V, Mu H, Leverson J, Nichols G, Reed J, et al. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017;32:748-760.e6 pubmed publisher
    ..The efficacy, together with the mechanistic findings, reveals the potential of simultaneously targeting these two apoptosis regulators and provides a rational basis for clinical testing of this therapeutic approach. ..